{"nctId":"NCT03311945","briefTitle":"Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM","startDateStruct":{"date":"2018-05-02","type":"ACTUAL"},"conditions":["HIV Infections","HIV-1-infection","HIV Seropositivity"],"count":33,"armGroups":[{"label":"Raltegravir + Lamivudine","type":"EXPERIMENTAL","interventionNames":["Drug: Raltegravir","Drug: Lamivudine"]}],"interventions":[{"name":"Raltegravir","otherNames":[]},{"name":"Lamivudine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients in the switch arm who have completed the 24-week follow-up of RALAM (NCT02284035) study and remain virologically suppressed (viral load \\<50 copies/mL) on dual therapy with lamivudine plus Raltegravir\n* Patients who have signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Pregnancy, lactation, or planned pregnancy during the study period\n* Any disease or history of disease which, in opinion of the investigator, might confound the results of the study or pose additional risk to patient treatment\n* Hepatitis B co-infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With Therapeutic Failure","description":"Proportion of patients that at least present one of the following events: virological failure, change in antirretroviral treatment for any reason, consent withdrawal, loss to follow-up or death.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Peripheral Mononuclear Blood Cells HIV-1 Reservoir","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Cholesterol Total","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Cholesterol LDL","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Cholesterol HDL","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Triglycerides","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Insulin Resistance (HOMA-IR)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Lumbar and Femoral Bone Mineral Density","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Plasma 25-OH Vitamin D Levels","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Urine Beta-2-microglobulin","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Estimated Glomerular Filtration Rate (Chronic Kidney Disease Epidemiology CollaborationI)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in Urine Protein/Creatinine Ratio","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Biomarkers of Inflammation IL-6","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Biomarker of Mononuclear Activation SD-163","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Biomarker of Mononuclear Activation SD-14","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Biomarker of Inflammation High Sensitivity C-reactive Protein","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Sleep Quality (Pittsburgh Sleep Quality Index) at","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in EQ-5D-5L","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Incidence of Adverse Events","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Viral Load","description":"Proportion of patients with viral load below ultrasensitive HIV-1 RNA detection limit (limit of detection 1 copy/mL) at 48 weeks","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":33},"commonTop":["Gastrointestinal","Systemic","Respiratory","Dermatological","Genitourinary"]}}}